All In Biotech

Drug Trial Radar · NCT06290141

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Aug 21, 2024

Primary completion

Jul 9, 2027

Study completion Jan 12, 2029

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Mar 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.

Conditions

  • Chronic Inflammatory Demyelinating Polyneuropathy

Interventions

  • riliprubartDrug

    Pharmaceutical form: Solution Route of administration: IV solution

  • PlaceboDrug

    Pharmaceutical form: Solution Route of administration: IV solution

  • riliprubartDrug

    Pharmaceutical form: Solution Route of administration: SC solution

  • PlaceboDrug

    Pharmaceutical form: Solution Route of administration: SC solution

  • IVIgDrug

    Pharmaceutical form: Concentrate for solution for infusion (or any other formulation approved locally) Route of administration: IV solution

  • PlaceboDrug

    Pharmaceutical form: Placebo to match intravenous immunoglobulin IVIg for IV infusio Route of administration: IV solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants experiencing a responseTime frame: Baseline to week 24
  2. Percentage of participants randomized to riliprubart who responded during part A and had a lasting response during the open-label treatment extension periodTime frame: Baseline to week 48

Locations

138 sites in 24 countries. Site status is shown where the registry gives one.

  • Alabama Neurology Associates- Site Number : 8400019

    Homewood, Alabama · Recruiting

  • HonorHealth Bob Bove Neuroscience Institute - Site Number : 8400014

    Scottsdale, Arizona · Recruiting

  • University Of Southern California- Site Number : 8400002

    Los Angeles, California · Recruiting

  • University of California Irvine - Manchester Pavilion- Site Number : 8400007

    Orange, California · Recruiting

  • IMMUNOe International Research Centers - Centennial- Site Number : 8400049

    Centennial, Colorado · Recruiting

  • Yale University School Of Medicine Department Of Neurology- Site Number : 8400018

    Fairfield, Connecticut · Recruiting

  • DM Clinical Research - Bradenton- Site Number : 8400044

    Bradenton, Florida · Recruiting

  • Research by Design, LLC- Site Number : 8400053

    Miami Lakes, Florida · Recruiting

  • AdventHealth Orlando- Site Number : 8400006

    Orlando, Florida · Recruiting

  • Endeavor Health - NorthShore Kellogg Cancer Center - Glenbrook- Site Number : 8400024

    Glenview, Illinois · Recruiting

  • University of Kansas Medical Center- Site Number : 8400010

    Kansas City, Kansas · Recruiting

  • Ochsner Medical Center - Jefferson Highway- Site Number : 8400030

    New Orleans, Louisiana · Recruiting

  • Wilmer Instit John Hopkins Hosp Univ Sch Medicine- Site Number : 8400015

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital-Genetics- Site Number : 8400009

    Boston, Massachusetts · Recruiting

  • Henry Ford Hospital- Site Number : 8400025

    Detroit, Michigan · Recruiting

  • Michigan State University- Site Number : 8400038

    East Lansing, Michigan · Recruiting

  • Washington University School of Medicine- Site Number : 8400037

    St Louis, Missouri · Recruiting

  • Profound Research- Site Number : 8400052

    Las Vegas, Nevada · Recruiting

  • Dent Neurologic Institute - Amherst- Site Number : 8400039

    Amherst, New York · Recruiting

  • Northwell Health Physician Partners Dermatology at Lake Success- Site Number : 8400051

    Lake Success, New York · Recruiting

  • Hospital for Special Surgery - Site Number : 8400041

    New York, New York · Recruiting

  • Columbia University Irving Medical Center- Site Number : 8400003

    New York, New York · Recruiting

  • Raleigh Neurology Associates- Site Number : 8400043

    Raleigh, North Carolina · Recruiting

  • University of Cincinnati Medical Center- Site Number : 8400020

    Cincinnati, Ohio · Recruiting

  • University Hospitals Cleveland Medical Center- Site Number : 8400033

    Cleveland, Ohio · Recruiting

  • Penn State Health Milton South Hershey Medical Center- Site Number : 8400042

    Hershey, Pennsylvania · Recruiting

  • Penn Medicine: University of Pennsylvania Health System- Site Number : 8400022

    Philadelphia, Pennsylvania · Recruiting

  • Austin Neuromuscular Center- Site Number : 8400040

    Austin, Texas · Recruiting

  • Gadolin Research - Beaumont- Site Number : 8400047

    Beaumont, Texas · Recruiting

  • Uthealth - The University Of Texas Health Sciences Center At Houston- Site Number : 8400050

    Houston, Texas · Recruiting

  • University of Vermont Medical Center- Site Number : 8400012

    Burlington, Vermont · Completed

  • University of Virginia- Site Number : 8400023

    Charlottesville, Virginia · Recruiting

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina · Recruiting

  • Investigational Site Number : 0320002

    Buenos Aires, Argentina · Recruiting

  • Investigational Site Number : 0320003

    Buenos Aires, Argentina · Recruiting

  • Investigational Site Number : 0560002

    Ghent, Belgium · Completed

  • Investigational Site Number : 0560001

    Leuven, Belgium · Recruiting

  • PSEG Centro de Pesquisa Clínica- Site Number : 0760009

    São Paulo, Brazil · Recruiting

  • L2IP - Instituto de Pesquisas Clínicas- Site Number : 0760006

    Brasília, Federal District, Brazil · Recruiting

  • Fundação Universidade Federal de Mato Grosso do Sul- Site Number : 0760020

    Campo Grande, Mato Grosso do Sul, Brazil · Recruiting

Showing 40 of 138 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.